NasdaqGM:BCAXBiotechs
Bicara Therapeutics (BCAX): Assessing Valuation After Breakthrough Therapy Designation and Early Trial Data Progress
Bicara Therapeutics (BCAX) just put a spotlight on its lead cancer program, pairing early Phase 1b data with an FDA Breakthrough Therapy designation, a one two punch that immediately sharpens the stock’s long term narrative.
See our latest analysis for Bicara Therapeutics.
The Breakthrough Therapy news arrives after a powerful run, with Bicara’s 1 month share price return of 24.32 percent and 3 month share price return of 48.09 percent. However, the 1 year total shareholder return is still...